Human DEK is an abundant and highly conserved nuclear protein that has long been implicated in carcinogenesis and autoimmune disorders (for a review, see references 50 and 60). Originally isolated from a specific subtype of acute myeloid leukemia (55) , the gene encoding DEK is expressed under the control of transcription factors E2F and YY1 (10, 49) . High levels of DEK support cell immortalization and inhibit both senescence and apoptosis, as shown in cells infected with highrisk human papillomavirus E7 (1, 62, 63) . DEK is also upregulated in a variety of aggressive human tumors, including retinoblastoma, colon and bladder cancer, and melanoma (e.g., see references 10, 19, 28, 30, and 37) .
In the nucleus, DEK is involved in a variety of DNA-and RNA-dependent processes, such as DNA replication (2) , splice site recognition (51) , and gene transcription. Here it can function as either an activator (9) or a repressor (16, 20, 45) . The diversity of these effects is in line with DEK's described function as a possible regulator of chromatin architecture, which may affect genome activity at various levels in a highly contextdependent manner. In fact, DEK has been shown in vitro to be a modifier of DNA higher-order structure, acting in concert with topoisomerase I to introduce constrained positive supercoils in closed circular DNA plasmids and simian virus 40 (SV40) minichromosomes (24, 25, 58, 59 ). Accordingly, DEK was shown to bind to DNA in a structure-specific rather than sequence-specific manner and to reduce the accessibility of chromatin to components of the replication machinery (2, 58) . Beyond its effects on DNA topology, DEK can modulate the activity of other chromatin-associated proteins, such as P/CAF and p300/CBP (27) , the p65 subunit of NF-B (45) , and the transcription factor AP2-␣ (9), as well as the nuclear splicing factor U2AF (51) .
Posttranslational modifications play an important role in regulating DEK's binding to DNA and chromatin proteins: acetylation and phosphorylation decrease DEK's affinity for DNA (11, 24) , while the interaction of DEK with U2AF requires phosphorylation (51) . How the posttranslational modification of DEK is regulated in vivo, however, is largely unclear. We recently observed a pronounced reduction in the phosphorylation level of DEK in cells undergoing cell death by apoptosis (53) .
Another posttranslational modification of DEK was identified in an in vitro transcription system derived from human nuclear extracts. Here, poly(ADP-ribosyl)ation of DEK by poly(ADP-ribose) polymerase 1 (PARP1) was required to displace DEK from a chromatin substrate and allow access of transcription factors (17) . The poly(ADP-ribosyl)ation of nuclear proteins by PARP1 is implicated in many aspects of genomic activity that require remodeling of local chromatin architecture, in particular, the repair of DNA lesions by the base excision repair pathway (reviewed in references 8 and 47) . The occurrence and significance of a potential PARP1-DEK interaction has not been investigated in vivo so far and could contribute to understanding the mechanisms underlying DEK's function in oncogenesis.
In addition, the observation that DEK is a substrate for poly(ADP-ribosyl)ation, resulting in the dissociation of DEK from DNA, suggests that under conditions of sustained PARP1 activation, DEK may be displaced from chromatin and eventually released from the nuclear compartment. This putative scenario could have important implications for the role of DEK in the pathogenesis of autoimmunity, another disease besides cancer in which DEK is crucially involved. Circulating anti-DEK autoantibodies are found in different autoimmune disorders, including systemic lupus erythematosus and sarcoidosis (14) . High concentrations of DEK are also present in synovial fluids from patients affected by juvenile rheumatoid arthritis/juvenile idiopathic arthritis (JRA/JIA) (35) . Prompted by our proteome analysis that highlighted a change in the phosphorylation status of DEK in dying cells (53) , we hypothesized that apoptosis could provide an attractive in vivo setting for the study of DEK's posttranslational modifications. Our results show that a fraction of DEK is heavily modified by phosphorylation and poly(ADP-ribosyl)ation in dying cells. These DEK species are efficiently released from chromatin and eventually from the cell, providing a further mechanism by which DEK can be presented to the immune system. Further, we demonstrate that DEK is involved in the repair of DNA strand breaks, thus supporting a role for DEK in the poly-(ADP-ribose)-dependent (PAR-dependent) maintenance of genomic integrity.
MATERIALS AND METHODS
Antibodies. For the detection of DEK, either a mouse monoclonal antibody (clone 2; BD Biosciences) or an affinity-purified polyclonal antibody (24) was used. Anti-phosphoserine H2AX antibodies (clone JBW301) were obtained from Upstate. HMG1-specific polyclonal antibodies were from Abcam (catalog no. ab18256), HMG2-specific polyclonal antibodies were from BD Biosciences, and anti-active caspase-3 antibodies were from Cell Signaling.
Mouse monoclonal antibodies recognizing PAR were immunopurified on a protein A column (Sigma) from 10H hybridoma cell culture supernatant (kind gift of M. Miwa and T. Sugimura) (26) . Mouse monoclonal antibodies directed against PARP1 were harvested from the culture supernatant of CII10 hybridoma cells (kind gift of G. G. Poirier).
DEK-specific autoantibodies were purified from the synovial fluid of one patient with a positive antinuclear antibody status (kind gift of David Glass, Cincinnati Children's Hospital Medical Center, Cincinnati, OH).
Cell culture procedures. Jurkat cells were grown in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillinstreptomycin. HeLa, the Phoenix amphotropic retroviral packaging cell line, and the lentiviral packaging cell line HEK 293 FT were grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% FCS, 100 U/ml penicillinstreptomycin. All cultures were maintained in a humidified atmosphere at 37°C and 5% CO 2 .
For in vivo labeling with [ 32 P]orthophosphate, Jurkat cells were washed three times with phosphate-and serum-free RPMI medium and then cultivated in phosphate-and serum-free medium supplemented with 40 mCi/ml of 32 Pi (carrier free; ICN) for the indicated time.
For the generation of a Jurkat cell line stably expressing a dominant-negative mutant of ICAD (43) , the retroviral expression vector pBABE-ICAD-dm was used to transfect Phoenix cells to produce high-titer retrovirus for infection. Briefly, 5 ϫ 10 6 cells were seeded in a 10-cm petri dish 24 h before being transfected with 20 g pBABE-ICAD-dm or pBABE DNA (empty vector) by using calcium phosphate. The medium was replaced after 24 h. The viruscontaining culture supernatant was harvested 48 h and 72 h after transfection and used immediately for the transduction of Jurkat cells. After filtration through a 0.45-m filter and addition of 4 g/ml Polybrene, the supernatant (at 48 h) was used to resuspend Jurkat cells at a density of 1 ϫ 10 5 cells/ml. The cell suspension was distributed in six-well plates and spin infected for 90 min at 32°C and 1,500 ϫ g. After 5 h at 37°C, the medium was replaced. The cells were collected 16 h later, and the spin transduction procedure was repeated with supernatant (at 72 h). Cells were then collected and cultured for 2 weeks in the presence of 1.5 g/ml puromycin. Resistant clones were isolated by dilution cloning in 96-well plates.
shRNA procedures. To achieve stable DEK knockdown in Jurkat and HeLa cells, third generation, self-inactivating lentiviral constructs were used. Two different systems were chosen for successful knockdown of DEK. For selection by enhanced green fluorescent protein (EGFP), three packaging vectors (pRSVrev, pMDLg/pRRE, and pHCMV-G, providing rev, gag, pol, and envelope protein G) and a control plasmid, H1-LV, producing no short hairpin RNA (shRNA) but producing EGFP as well as a double anti-DEK shRNA-producing construct (H1/U6LV_1450/960, targeting DEK mRNA at nucleotide positions 960 and 1450) were used. For puromycin selection, two plasmids from the Sigma Mission shRNA library, PLKO.1_DEK832 and PLKO.1_DEK1165 (targeting DEK mRNA at nucleotide positions 832 and 1165), were used to knock down DEK. As a control vector, PLKO.1_PURO, coding for the puromycin resistance gene and no shRNA, was used. Viruses produced by using these vectors are referred to as GFP-control, DEK-DL-LV, Puro-c, DEK-832, and DEK-1165.
A 4-day infection protocol was used for lentivirus production and infection of target cells. HEK 293 FT cells were seeded on 10-cm dishes on the first day to be 90% confluent at time of transfection. On the second day, HEK 293 FT cell culture medium was supplemented with 25 g chloroquine prior to transfection with 4 g of each individual plasmid using calcium chloride. Eight hours posttransfection, medium was replaced and virus-containing supernatant was harvested at 12, 24, and 36 h posttransfection. For the infection of target cells, virus-containing supernatant was filtered through 0.45-m filters and supplemented with 4 g/ml Polybrene prior to incubation. The infection of target cells was repeated twice for a total of 10 h. Selection by puromycin (2 g/ml for Jurkat and 1 g/ml for HeLa) was started 48 h postinfection for up to 10 days. For sorting by fluorescence-activated cell sorter analysis, cells were grown for 72 h and sorted by GFP gating. The sorted cells were 100% GFP positive and kept in culture for a maximum of five passages.
Preparation of cell extracts, immunoprecipitation, and immunoblot analysis. Jurkat cells were seeded in dishes of appropriate size at a density of 5 ϫ 10 6 cells/ml in serum-free medium. After 30 min of incubation at 37°C, apoptosis was induced by treatment with 3% CD95-L-containing culture supernatant from CD95-L-expressing N2A cells (42) . For the experiments represented in Fig. 1 , cells were harvested by centrifugation (500 ϫ g for 5 min at 4°C), washed once in ice-cold phosphate-buffered saline (PBS), and resuspended in cell lysis buffer A (clbA: 0.5% NP-40, 1% Triton X-100, 50 mM Tris-HCl, pH 7.5) or clbA50 (clbA supplemented with 50 mM NaCl) supplemented with protease inhibitors (Complete; Roche) and phosphatase inhibitors (10 mM NaF and 1 mM Navanadate). After centrifugation (20,000 ϫ g for 10 min at 4°C), the supernatant was frozen in liquid N 2 and the pellet was resuspended in sodium dodecyl sulfate (SDS)-lysis buffer (50 mM Tris-HCl, pH 8.0, 0.5% SDS, 1 mM dithiothreitol) and heated at 95°C for 10 min. The cell debris was removed by centrifugation at 20,000 ϫ g for 10 min. S-20 extracts for in vitro phosphorylation assays were prepared at the indicated times after CD95-L treatment, and the assay was performed as described previously (24) .
For the detection of extracellular DEK, medium was collected from cultures treated to undergo apoptosis for the time periods indicated. The medium was centrifuged twice for 5 min at 20,000 ϫ g, and the proteins were precipitated by using methanol-chloroform as described below. For immunoprecipitation of the radiolabeled protein, Jurkat cells were harvested by centrifugation (500 ϫ g for 5 min at 4°C) and washed twice with ice-cold PBS and once with hypotonic buffer (20 mM NaCl, 20 mM HEPES, pH 7.6, 5 mM MgCl 2 , protease inhibitors, and phosphatase inhibitors NaF and Na-vanadate), followed by incubation in hypotonic buffer (supplemented with 0.5% NP-40 and protease and phosphatase inhibitors) for 15 min on ice at a cell density of 2 ϫ 10 7 cells/ml. The soluble material (cytosol/nucleosol) was recovered by centrifugation (500 ϫ g for 5 min at 4°C). The insoluble material was either dissolved in 2% SDS and subjected to gel electrophoresis or resuspended in hypotonic buffer containing 450 mM NaCl for the immunoprecipitation of chromatin-bound DEK. In the latter case, the suspension was incubated for 15 min on ice, insoluble material was pelleted (1,000 ϫ g for 10 min), and the supernatant was incubated with DEK-specific antibodies. For the detection of modified DEK in immunoblots, proteins of the cytosolic/nucleosolic fraction were immediately precipitated with methanol-chloroform as described previously (61) . The precipitated material was dissolved in 2% SDS for gel electrophoresis. For immunoprecipitation, 5 g of affinitypurified polyclonal DEK antibodies was used for the equivalent of 1 ϫ 10 6 cells. After 1 h of incubation on ice, 30 l of a 50% protein A-Sepharose suspension (Amersham Pharmacia) was added and the mixture was rolled at 4°C for another hour. The immune complexes were washed three times with 1 ml each of extraction buffer (450 mM NaCl, 20 mM HEPES, pH 7.4, 0.5 mM MgCl 2 ), followed by dissociation from the beads with 2% SDS and 5% ␤-mercaptoethanol at 37°C for 1 h. The samples were separated by SDS-polyacrylamide gel electrophoresis (PAGE), blotted to nitrocellulose (Schleicher & Schuell), and analyzed by autoradiography and immunoblotting.
Immunofluorescence microscopy. For the detection of phosphorylated ␥H2AX foci, HeLa cells treated with neocarzinostatin were fixed in PBS containing 4% paraformaldehyde for 10 min at room temperature, followed by two washes in PBS and one in PBS-50 mM NH 4 Cl for 10 min each. Cells were permeabilized with 0.2% Triton in PBS for 5 min at room temperature. After extensive washings with PBS, coverslips were incubated with 1% bovine serum albumin (BSA) in PBS for 30 min and then with anti-phospho H2AX antibody diluted 1:500 in PBS containing 10% normal goat serum for 1 h at room temperature. Alexa Fluor 568-conjugated goat anti-mouse immunoglobulins were used as secondary antibodies at a dilution of 1:400. ␥H2AX-positive foci were visualized by laser scanning confocal microscopy by using a Zeiss LSM510 Meta microscope. Identical settings were used for each experiment. z stacks consisting of 10 sections (0.6-m interval) were recorded. Image analysis was performed on maximum intensity projections of the six z planes by using ImageJ. The mean signal intensity of the nuclei was determined for at least 200 nuclei per experimental condition.
Apoptosis assays. (i) Chromatin condensation. HeLa cells were seeded at a density of 1 ϫ 10 5 /ml 24 h prior to the experiment. Jurkat cells were plated at a density of 2.5 ϫ 10 5 /ml 30 min prior to the experiment in 96-well plates, followed by treatment with camptothecin (Sigma), etoposide (Sigma), neocarzinostatin (Sigma), CD95-L (42), or lz-TRAIL (57) at the concentrations indicated. After 12 h, cells were fixed with 5% formaldehyde, stained with 1.5 g/ml Hoechst 33342 and inspected microscopically. Cells with characteristically condensed or fragmented nuclei were scored as apoptotic.
(ii) Caspase activity assay. A total of 3 ϫ 10 5 HeLa cells were seeded in six-well plates 24 h prior to the experiment and treated with camptothecin (500 nM), etoposide (50 M), or neocarzinostatin (300 ng/ml). At the indicated time points, the cells were placed on ice and after the addition of a 3ϫ protease inhibitor solution in PBS (amounting to one-third of the culture volume), cells were gently scraped off the dish and collected by centrifugation. Cells were lysed in 25 mM HEPES, pH 7.5, 5 mM MgCl 2 , 1 mM EGTA, and 0.5% Triton X-100, and the cleavage of DEVD-7-amino-4-trifluoromethyl coumarin (afc) (40 M) was monitored fluorometrically in reaction buffer (50 mM HEPES, pH 7.5, 10 mM dithiothreitol, 1% sucrose, 0.1% CHAPS {3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate}) over a period of 20 min at 37°C, with a ex (excitation wavelength) value of 390 nm and a em (emission wavelength) value of 505 nm. The activity was calibrated by using afc standard solutions. Measurements were run in triplicate. Caspase-3 processing was detected in whole-cell lysates by immunoblot anal- ysis using neo-epitope-specific antibodies recognizing the large fragment (p17/ p19) of activated caspase-3.
(iii) DNA laddering. Low-salt extract corresponding to 8 ϫ 10 5 Jurkat cells was deproteinated by treatment with 100 g/ml proteinase K for 2.5 h at 37°C. The DNA was precipitated with 2.5 volumes of ethanol at Ϫ20°C overnight and recovered by centrifugation (20,000 ϫ g for 20 min at 4°C). After RNase treatment (100 g/ml, 37°C, 30 min), oligonucleosomal fragments were visualized by agarose gel electrophoresis.
Sucrose density gradient centrifugation. Sucrose density gradient analyses were essentially performed as described previously by Kappes et al. (24) . Briefly, Jurkat cells were washed twice in equilibrated serum-free RPMI medium and seeded at a density of 5 ϫ 10 6 cells/ml. After 2.5 h of apoptosis induction by 3% CD95-L, cells were harvested by centrifugation, washed with ice-cold PBS, and lysed with clbA50 buffer. Soluble material (low-salt fraction) was separated by centrifugation (1,000 ϫ g for 10 min at 4°C) and layered on sucrose density gradients (5% to 40% sucrose prepared in clbA50 without NP-40 and Triton X-100). After 14 h of centrifugation at 160,000 ϫ g (SW-41 rotor; Beckman), gradients were fractionated and individual samples were analyzed by agarose electrophoresis and immunoblotting.
Poly(ADP-ribosyl)ation and PAR-binding assays. (i) in vitro poly(ADP-ribosyl)ation of recombinant DEK. Reactions were carried out in a volume of 50 l containing 100 mM Tris-HCl, pH 7.8, 10 mM MgCl 2 , 1 mM dithiothreitol, and 10 M of the double-stranded octameric palindromic oligonucleotide GGAA TTCC (Invitrogen) in the presence of DEK and NAD ϩ (Sigma) at 1 mM (Fig.  3A) or the various concentrations indicated (see Fig. S3 in the supplemental material). As a positive control, 50 pmol recombinant p53 was included (34) . The reactions were started by adding 565 ng of recombinant human PARP1 (100 nM) and incubated at 37°C for 15 min on a shaker. Recombinant human PARP1, human p53, and DEK were overexpressed in insect cells by using the baculovirus system as described previously (15, 24) . The reactions were stopped by the addition of an equal volume of 2ϫ PAGE loading buffer, followed by 5 min of incubation at 95°C. For the electrophoretic mobility shift assay (EMSA) and the topology and aggregation assays, samples were further processed as described below. The proteins were blotted onto nitrocellulose by using a wet blot chamber (Bio-Rad), and the filters were then incubated in Tris-buffered saline-Tween (TBS-T) with 5% (wt/vol) skim milk powder at room temperature. Incubations with primary antibodies were in TBS-T with milk at 4°C overnight. Filter washings and incubations with peroxidase-coupled secondary antibodies were in TBS-T only. PAR was detected with monoclonal antibody 10H at a 1:200 dilution. For the detection of DEK and PARP1, filters were stripped and reprobed with polyclonal DEK-specific antibodies (1:10,000) and monoclonal PARP-specific antibodies CII10 (1:5), respectively.
(ii) PAR overlay blot. Increasing amounts of recombinant DEK (0 to 50 pmol) and BSA (100 pmol) were separated by 14% PAGE and blotted onto nitrocellulose by semidry transfer (Amersham Biosciences). Filters were washed in TBS-T and incubated overnight at 4°C in TBS-T containing 5 nmol (1 M) of purified PAR. Filters were subsequently washed in TBS-T-1 M NaCl and TBS-T-5% (wt/vol) skim milk powder. The detection of bound PAR polymers was performed as described above by using 10H antibody, followed by Ponceau S staining to visualize the proteins.
Assessment of DNA repair by FADU. The fluorometric analysis of DNA unwinding (FADU) assay is based on the time-dependent denaturation of DNA under moderate alkaline conditions. Denaturation starts from DNA breakpoints (single-and double-strand breaks) and is terminated by neutralization. DNA that remains double stranded is detected by the addition of the intercalating dye SYBR green, a fluorescent compound specific for double-stranded DNA, and measured fluorometrically. Here, we employed an automated version of the FADU assay that ensures very reliable and reproducible results (A. MorenoVillanueva et al., submitted for publication). Briefly, HeLa cells (2.5 ϫ 10 5 /ml) were subjected to a short pulse treatment with camptothecin (250 nM), etoposide (30 M), or neocarzinostatin (2 g/ml) at 37°C for 5 min. Cells were then collected by centrifugation, resuspended in medium containing 5% FCS, and divided into equal 100-l aliquots corresponding to 6 ϫ 10 4 cells. Aliquots were then incubated at 37°C for different times to allow DNA repair. Cells were then collected on ice and subjected to the FADU procedure by using a pipetting robot (Genesis RSP 100; Tecan). The fluorescence intensity values are a measure of the amount of double-stranded DNA present in each sample. DNA repair is calculated as the percent reduction of the treatment-induced loss of doublestranded DNA. Values above 100% indicate that cells also repair the basal DNA lesions present in the absence of treatment.
EMSA and topology and aggregation assays. EMSAs and topology assays were carried out essentially as described previously by Kappes et al. (24, 25) . Aggregation assays were performed according to the method of Böhm et al. (5) . For in vitro poly(ADP-ribosyl)ation, recombinant His-DEK was first dephosphorylated with -phosphatase according the manufacturer's instructions (NEB) and treated as described above. Poly(ADP-ribosyl)ated DEK was swim filter dialyzed in the presence of purified BSA against nE300 (20 mM HEPES, pH 7.6, 300 mM NaCl, 10 mM sodium bisulfite, and 1 mM EDTA) for 90 min at 4°C prior to being used in the assays.
RESULTS
DEK is released from chromatin during apoptosis. We set out to determine whether the induction of apoptosis affects the characteristic behavior of DEK as a chromatin-binding protein. In control Jurkat cells, DEK elutes from chromatin at 250 mM NaCl. No DEK is present in the cytosolic/nucleosolic fraction and a fraction isolated at low ionic strength (50 mM NaCl) (Fig. 1A) , confirming previous data obtained with HeLa cells (23) . In contrast, increasing amounts of DEK were recovered in a low-salt extract of Jurkat cells undergoing apoptosis triggered by CD95-L (29). This effect seems to be unique to DEK since no change in the recovery of HMG1 and HMG2 is observed under the same conditions (Fig. 1B) . DEK's appearance in low-salt extracts coincides with the progression of several apoptosis parameters, such as chromatin condensation, caspase-3/caspase-7 activity, and oligonucleosomal DNA laddering ( Fig. 1C and D) , and is dependent on caspase activity, as shown by experiments performed in the presence of the caspase inhibitor zVAD-fmk (Fig. 1E) . The increased recovery of DEK under low-salt conditions is also observed in cells undergoing apoptosis after staurosporine or camptothecin treatment (Fig. 1F) .
DEK released from chromatin in apoptosis is posttranslationally modified. According to our previous in vitro studies, DEK's interaction with chromatin is modulated by phosphorylation (24, 53) . We therefore wished to assess whether phosphorylation contributes to the release of DEK from apoptotic nuclei. To this end, we examined the phosphorylation level of DEK in subcellular fractions of cells treated with CD95-L. DEK present in the soluble fraction (cytosol plus nucleosol) was highly phosphorylated during apoptosis, as revealed by the immunoprecipitation of the radiolabeled protein ( Fig. 2A , bottom left panel). Further extraction of the nuclear pellet with 450 mM NaCl yielded chromatin-bound DEK, evincing a significantly reduced level of phosphorylation compared to the level for control cells (compare chromatin fractions with and without CD95-L in Fig. 2A) . These results are consistent with our proteome analysis that was performed on nuclear pellets of a cell-free apoptosis reaction and showed the hypophosphorylation of DEK (53) . These data further indicate that during apoptosis, the cellular pool of DEK separates into two fractions, a soluble hyperphosphorylated one that is released from chromatin and a second hypophosphorylated one that is retained on apoptotic chromatin. Additional in vitro studies suggest that apoptotic phosphorylation of DEK is carried out by kinases distinct from the previously described CK2. These kinases are not susceptible to inhibition by 4,5,6,7-tetrabromobenzotriazole (39) and await further characterization (see Fig.  S1 in the supplemental material).
Interestingly, less DEK was detected in the extracts used for immunoprecipitation than in the low-salt fraction shown in Fig.  1B and, furthermore, these extracts contained phosphorylated DEK species of higher molecular weights, resulting in a smear in the autoradiogram (Fig. 2A, left panel) . A systematic comparison of different lysis and sample preparation procedures indicated that the recovery of apoptotically released DEK strongly depends on buffer composition and sample handling. High-molecular-weight DEK species appeared exclusively in cytosolic/nucleosolic fractions (Fig. 2B, bottom left panel) prepared in 0.5% NP-40 and precipitated immediately with methanol-chloroform (61), but did not appear if Triton X-100 was present and/or samples were incubated on ice (see Fig. S2 in the supplemental material).
The unstable nature of these DEK species, their molecular weight range, and the lack of discrete bands in immunoblots were suggestive of poly(ADP-ribosyl)ation. Supporting this assumption, DEK is poly(ADP-ribosyl)ated in in vitro assays using recombinant purified PARP1 and NAD ϩ , the direct substrate of this modification reaction (Fig. 3A, top and middle  panels) . The poly(ADP-ribosyl)ation of DEK occurred at physiological NAD ϩ concentrations and was augmented with increasing substrate concentrations, underscoring the specificity of the reaction (see Fig. S3 in the supplemental material) . Accordingly, immunoprecipitation experiments using DEK-or PAR-specific antibodies showed that DEK is found poly(ADPribosyl)ated in vivo in apoptotic cells (Fig. 3B) . The level of modification detected by this method was low compared to the immediate precipitation of modified DEK species from cell lysates, most likely due to the degradation of the typically unstable PAR moieties during antibody incubation. The association between DEK and PARP1 is further supported by sucrose gradient density studies of micrococcal nuclease-digested chromatin. Here, DEK and PARP1 colocalize preferentially to regions of active chromatin present in the soluble supernatant of the micrococcal nuclease reaction (see Fig. S4 in the supplemental material). As a consequence of poly(ADPribosyl)ation, DEK loses both its DNA-binding activity and the ability to alter DNA topology as shown by EMSA, aggregation assays, and topology assays (Fig. 3C) .
Further, the ability of DEK to interact noncovalently with PAR polymers was demonstrated by a PAR overlay assay, in which recombinant His-tagged DEK blotted onto nitrocellulose was incubated with purified PAR (Fig. 3D, top panel) . High amounts of BSA (100 pmol versus 50 pmol of DEK) showed no PAR binding (for a presentation of a further control for the specificity of DEK's binding to PAR, see Fig. S5 in the supplemental material).
DEK is involved in repair of DNA lesions induced by radiomimetic drugs and topoisomerase poisons. Since the activation of PARP1 and the synthesis of ADP-ribose polymers are early events in DNA damage signaling and repair pathways (8), we were interested in determining whether DEK is involved in these functions. We therefore created stable Jurkat and HeLa cell lines with impaired DEK expression utilizing lentiviral shRNA delivery systems. DEK expression was significantly decreased in these cells, more effectively so in HeLa cells than in Jurkat cells (see Fig. S6 in the supplemental material) . Furthermore, we observed different knockdown levels by using the commercially available monoclonal DEK-specific antibody versus a rabbit polyclonal DEK-specific antibody (data not shown). These antibodies also differed in their abilities to detect modified DEK (see Fig. S7A , S7B, and S7C in the supplemental material).
The DNA repair activity of DEK knockdown cells was compared to that of control cells by two independent approaches. First, we analyzed the induction and persistence of histone H2AX phosphorylation on serine 139, a well-established marker of DNA double-strand breaks (54). Cells were sub- At the indicated time points, apoptotic and control (co) cells were harvested and lysed with hypotonic buffer containing 0.5% NP-40 to yield soluble proteins (cytosol/nucleosol). The remaining nuclear and chromatin structures were extracted with 450 mM NaCl (chromatin bound). Equal amounts of the individual fractions were analyzed by immunoblotting with PARP1-or DEK-specific antibodies (␣-PARP or ␣-DEK). Immunoprecipitations (IP) were carried out by the addition of 5 g affinity-purified DEK-specific polyclonal antibodies to the individual fractions in the presence of 0.5% NP-40. Immune complexes were analyzed by autoradiography (lower panel) and by immunoblotting with DEK-specific monoclonal antibodies (Mab) (upper panel). (B) Jurkat cells, either untreated (Ϫ) or stimulated to undergo apoptosis with 3% CD95-L (ϩ) for the indicated times, were lysed with hypotonic buffer containing 0.5% NP-40 to yield soluble proteins (cytosol and nucleosol). The remaining nuclear structures were extracted with 450 mM NaCl (chromatin bound). Individual fractions were precipitated immediately with methanol-chloroform and subjected to immunoblot analysis with DEK-specific polyclonal antibodies (lower panel). The same blot was reprobed with PARP1-specific monoclonal antibodies to monitor PARP1 cleavage as a marker for apoptosis progression (upper panel). jected to a pulse treatment with neocarzinostatin (36) and fixed immediately or allowed to recover for 4 h or 8 h prior labeling with ␥H2AX-specific antibodies (Fig. 4A) . ␥H2AX-specific signals in the nucleus were quantified by confocal microscopy. DNA repair was expressed as the decrease of the averaged nuclear signal at 4 h and 8 h as a percentage of the signal intensity obtained immediately after treatment. In cells with downregulated DEK expression, the loss of ␥H2AX-specific staining was markedly reduced, indicating that positive foci persisted over time ( Fig. 4B and C) . Similar observations were also made for cells treated with an alkylating DNA-damaging agent, N-methyl-NЈ-nitro-N-nitrosoguanidine (data not shown). It is also noteworthy that no significant increase in ␥H2AX-specific staining was observed after DEK knockdown in the absence of genotoxic stress.
As a second approach, we used an automated version of the FADU assay, a fast and highly reproducible fluorometric method for quantifying both single-and double-strand DNA breaks (Moreno-Villanueva et al., submitted). Repair activity was compared in control and DEK knockdown cells challenged either with neocarzinostatin or with the topoisomerase inhibitors camptothecin and etoposide (Fig. 5) . Corroborating the data obtained by ␥H2AX immunostaining, DEK knockdown cells displayed a reduced ability to resolve DNA strand breaks compared to the controls. Interestingly, the magnitude of the effect was small relative to the difference in persistence of ␥H2AX-positive foci, suggesting that DEK may be more involved in the repair of double-strand breaks by nonhomologous end joining and homologous recombination rather than in base excision repair, which is the end point detected by the FADU assay.
Inhibition of DEK expression sensitizes cells toward genotoxic stress. Having established that loss of DEK interferes with the signaling involved in DNA repair or DNA repair itself, we investigated whether this loss would also lower the threshold for DNA damage-induced cytotoxicity. Apoptosis induced by camptothecin, etoposide, and neocarzinostatin was assessed in DEK knockdown and control HeLa cells by scoring for condensed nuclei. As shown in Fig. 6 , interference with DEK expression results in a marked sensitization toward these DNA-damaging agents, while it had no influence on the re- structs, confirming the specificity of these effects (see Fig. S9 in the supplemental material). DEK modified and released during apoptosis is potentially immunogenic. In addition to its possible involvement in DNA repair and DNA damage signaling, DEK was shown to be a potent autoantigen and was also proposed to be a mediator of inflammation (35) . Therefore, the presence of posttranslation- Cells were treated with either 500 nM camptothecin, 50 M etoposide, 300 ng/ml neocarzinostatin, or 300 ng/ml TRAIL for the indicated times. Aliquots were taken for microscopic evaluation of apoptosis as described above for panel A, and caspase-3/caspase-7-like activity was measured for the corresponding lysates by DEVD-afc cleavage (also see Fig. S8 in the supplemental material). Samples from control untreated cells were taken at the end of each time course and showed neither nuclear condensation nor caspase activation. Measurements were performed in triplicate. Error bars indicate standard deviations. ally modified DEK in soluble, non-chromatin-bound fractions of apoptotic cells could represent a specific portion of the cellular DEK pool that may be extruded into the extracellular milieu during apoptosis and potentially contribute to the proinflammatory and immunogenic functions of this protein.
We therefore wished to detail the apoptotic release of DEK and asked whether DEK is extruded from apoptotic nuclei in association with oligonucleosomal fragments. To this end, we generated Jurkat cells devoid of oligonucleosomal DNA cleavage due to the expression of a dominant-negative inhibitor of the caspase-activated DNase CAD. These cells underwent apoptosis to the same extent as did controls ( Fig. 7A; see Fig.   S10 in the supplemental material); however, oligonucleosomal laddering in response to CD95-L was completely suppressed (Fig. 7A, left panel) (44) . Immunoblot analysis showed that despite the inhibition of CAD, a significant amount of DEK could still be detected in low-salt extracts (Fig. 7A, right  panel) . Thus, DEK can be released from nuclei independently of oligonucleosomes, a finding further confirmed by sedimentation analysis in sucrose density gradients (Fig. 7B) . While a part of DEK present in low-salt apoptotic extracts comigrated with oligonucleosomes, a substantial amount was found in the top, DNA-devoid fractions of the gradient. DEK present in these fractions is heavily posttranslationally modified, as indi- Fig. 1 or 2B ). Soluble chromatin fragments and proteins were layered on sucrose density gradients (5% to 40% sucrose in the appropriate buffer without NP-40 and Triton X-100) and centrifuged for 14 h (160,000 ϫ g at 4°C) (SW-41 rotor; Beckman). Individual fractions were analyzed by agarose gel electrophoresis (1%) for DNA ( We estimated that about 30% of the total DEK released was found in a free, non-chromatin-bound form. We next assessed whether the generation of highly modified, soluble DEK could lead to the release of the protein in the cell culture supernatant. Indeed, we could detect extracellular modified DEK regardless of the apoptosis trigger (Fig. 7C) . This contributes to the possibility of poly(ADP-ribosyl)ated DEK being exposed to the immune system and acting as a self-antigen. We therefore were interested in whether DEKspecific autoantibodies present in the synovial fluids of JRA/ JIA patients (data not shown) were capable of detecting poly-(ADP-ribosyl)ated DEK. We indeed found that DEK-specific autoantibodies from synovial fluids efficiently detected poly-(ADP-ribosyl)ated DEK (Fig. 7D) . In summary, these data support the notion that under conditions of insufficient phagocytic clearance, apoptosing cells may represent a source of highly immunogenic DEK forms and could contribute to the generation of DEK autoantibodies.
DISCUSSION
A number of in vitro studies clearly established DEK as a modifier of chromatin superhelical density due to its biochemical properties (2, 25, 58, 59 ). Concurrently, DEK was shown to have pleiotropic functions in cells, affecting the replication, splicing, and transcription of different genes (9, 27, 33, 45) , thus making it difficult to pinpoint the functional targets of DEK in the nucleus. The relevance of DEK in chromatin homeostasis is underscored by its strong association with oncogenesis, while an additional potential role in inflammation is supported by its potent autoantigenic and chemotactic activity. In order to decipher the mechanisms underlying DEK's activity on the genome and to understand how its deregulation may result in disease, more information is needed about the mechanisms regulating the binding of DEK to chromatin in vivo.
Here, we show that under stress conditions (e.g., apoptosis), DEK is removed from chromatin, both in association with oligonucleosomes and in a free form. Released DEK is hyperphosphorylated, while the remaining chromatin-associated DEK fraction is significantly less phosphorylated compared to untreated cells. These results are consistent with the existence of a dynamic equilibrium on chromatin between dephosphorylated and phosphorylated DEK, where the dephosphorylated form anchors the phosphorylated one to chromatin via intermolecular interactions, as supported by recent in vitro data (24) . The second posttranslational modification of DEK that we demonstrate in cells undergoing apoptosis is poly(ADPribosyl)ation. This modification, which is traditionally associated with DNA damage, is observed also in cells treated with CD95-L, although this is not a DNA-damaging agent per se. However, a transient early burst of PARP1 activity has already been described after the stimulation of death receptors by CD95-L (48), possibly involving the generation of reactive oxygen species and oxidative DNA lesions (52) .
Poly(ADP-ribosyl)ation in concert with phosphorylation leads to the dissociation of DEK from chromatin and abolishes the chromatin folding activity of DEK (this work; 17). DEK also binds isolated ADP-ribose polymers noncovalently with very high affinity. In fact, we were able to identify several PAR-binding consensus motifs (40) in the DEK primary sequence (data not shown). This noncovalent interaction may contribute in the recruitment of DEK to poly(ADP-ribosyl) ated protein complexes present on chromatin or chromatin fragments.
Taken together (Fig. 8) , these data support the notion that apoptosis elicits a specific and unique posttranslational modification pattern of DEK that weakens the binding of DEK to DNA and, due to increased phosphorylation, favors the formation of protein-protein complexes. The detection of such modified DEK and DEK-DNA complexes in soluble fractions and culture supernatants from apoptosing cells suggests that these cells, if not promptly cleared, could become a source of immunogenic DEK. This suggestion is supported by the observation that circulating DEK-autoantibodies from synovial fluids of a JRA/JIA patient efficiently detected poly(ADP-ribosyl)ated DEK (Fig. 7) . We recently showed that DEK can be secreted from activated, nonapoptotic macrophages, which represents one possibility for the generation of DEK autoantibodies (35) . Cell death could thus provide a second and new pathway besides cell activation and exosomal secretion. DEK release from apoptotic cells could also exacerbate inflammatory reactions. In fact, we have recently demonstrated that DEK present in the extracellular milieu has chemoattractant properties, stimulating the migration of T cells, NK cells, and neutrophils (35) . The finding that DEK may be extruded from dying cells extends the similarity between this protein and HMG1, a member of the "high-mobility-group" family of architectural chromatin proteins. Different from DEK, HMG1 is released from necrotic cells and not from apoptotic cells (46) . However, this paradigm has been challenged by recent studies reporting the release of HMG1 during apoptosis [3, 22] ), which is consistent with the presence of HMG1 in cell culture supernatants from CD95-L-and neocarzinostatin-treated cells (Fig.  7C) . HMG1, like DEK, can exit cells via an active, nonclassical secretory pathway (18, 56) , displays chemotactic activity (12, 64) , and is heavily posttranslationally modified by acetylation, phosphorylation, methylation, and poly(ADP-ribosyl)ation (6, 13, 21, 65) . Whether DEK, like HMG1, fulfils the criteria of an "alarmin" (a term introduced recently to designate endogenous molecules that, if present extracellularly, signal cell and tissue damage [4] ) is the subject of ongoing studies.
Concerning the intracellular function of DEK, we addressed the question of whether DEK, as a poly(ADP-ribosyl)ated protein, may be involved in DNA repair. Our results show that a knockdown of DEK expression impairs the ability of cells to resolve DNA lesions and increases sensitivity to DNA-damaging agents. Interestingly, the contribution of DEK to DNA repair becomes most evident when cells are challenged with drugs that are potent activators of PARP1, such as the topoisomerase I inhibitor camptothecin and the inducer of doublestrand breaks neocarzinostatin, but not the topoisomerase II poison etoposide (7) . This further strengthens the notion of a functional relationship between PARP1 and DEK in DNA repair. Further data, such as the demonstration that DEK is a substrate for PARP1 activity in vivo and that the two proteins share a similar distribution on open chromatin regions (see Fig. S4 in the supplemental material), suggest that DEK may be an important transducer of PAR-dependent signaling pathways even beyond the repair of damaged DNA. This sugges-tion is corroborated by data from the literature showing that PARP1, in a manner similar to that of DEK (58), binds to (and is activated by) undamaged DNA with distorted, non-B structures, such as cruciforms, hairpins, and loops (32) . Moreover, PARP1 and DEK were both found in a chromatin fraction enriched for the variant histone macroH2A (38) , a marker for heterochromatin.
Finally, we observe that the degree of sensitization toward genotoxic treatment achieved by the inhibition of DEK expression is much more pronounced than the corresponding impairment of DNA repair activity, suggesting the existence of further mechanisms of DEK-dependent cytoprotection. These further mechanisms may involve the up-or downregulation of apoptosis regulatory genes, such as those encoding the antiapoptotic proteins bcl2 (31, 41) and cIAP2 (45) . A role for p53, as proposed previously (62) , is unlikely, since the HeLa cell line used in this study did not reveal any change in p53 amount or activation status upon DEK knockdown (data not shown) and Jurkat cells are p53 negative.
In summary, by studying DEK in the context of cellular stress and apoptosis, this work unravels intriguing new aspects concerning both the extracellular and intracellular functions of this protein. The results point at dying cells as a so-far-unrecognized and relevant source of potentially autoantigenic DEK and at a role for DEK in the response to genotoxic damage. While our work implicates poly(ADP)ribosylation in both damage-associated aspects of DEK function, understanding the involvement of this protein in the growing number of PAR-dependent pathways regulating genome activity under physiological conditions is a challenging question for the future. PARP1 and a yet-unidentified kinase(s) are also triggered, resulting in the phosphorylation and poly(ADP)ribosylation of the protein (4). DEK leaves the nucleus both bound to oligonucleosomes and in a DNA-free form (5) . Modified DEK is released into the extracellular space, where it is recognized by antibodies from JRA/JIA patients (6) . In the absence of DEK, cells are more sensitive to genotoxic damage and are more prone to activate caspases (7), partly due to impaired DNA repair. 
